Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Earnings season marches on, with Eli Lilly among the big names yet to report this week. President Trump has said he will name replacements this week for Federal Reserve governor Adriana Kugler and ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on genetics and financial implications.

Eli Lilly's oral GLP-1 drug orforglipron shows promise in weight loss, with significant results in a 72-week trial, aiming for 2025 global approval.

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down By Ty Roush, Forbes Staff. Ty Roush is a breaking news reporter based in New York City.

So why did Lilly's share price sink like a brick today? The company also announced results from a phase 3 study of its oral GLP-1 agonist, orforglipron, that caused concerns.

Lilly’s stock tumbled as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.